Search

Tebipenem pivoxil

[L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy. … [L57979] The FDA approved tebipenem pivoxil on June 17, 2026, for complicated urinary tract infections including pyelonephritis caused by designated susceptible organisms in adult patients who have

Crovalimab

[A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Ferumoxides

Mecamylamine

Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Thioproperazine

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually ...

Anacaulase

[A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.

GI-4000

A vaccine containing a heat-killed recombinant <em>Saccharomyces cerevisiae</em> yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant

Calcipotriol

Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Triheptanoin

[A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612] … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.

Moclobemide

Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (